---
title: "Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: CT-AMT-130-01"
description: "Formulary evidence on Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: CT-AMT-130-01. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 62 evidence topics quoted from 21 sources."
canonical: "https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence/ct-amt-130-01"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: CT-AMT-130-01

<a id="heading-3.1.2"></a>

## 3.1.2 CT-AMT-130-01

<a id="heading-3.1.2.1"></a>

### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

#### Safety and proof of concept in a first-in-human study

> “This is the first study of AMT-130 in patients with early manifest HD and is designed to establish safety and proof-of-concept (PoC).”
> “Cohort 4 will further evaluate the safety of high dose AMT-130 in participants with low striatal volume.”

Source: [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493)

<a id="topic-3.1.2.1-2"></a>

#### Objective described in March 2022

> “The ongoing Phase I/II clinical trial of AMT-130 is a randomized, sham controlled, double-blinded study to explore the safety, tolerability, and proof of concept of AMT-130 in patients with early manifest Huntington’s disease.”

Source: [uniQure press release, enrollment of first two cohorts (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-completion-patient-enrollment-first-two)

<a id="heading-3.1.2.2"></a>

### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

#### United States study sites in the registry record

| Site | City |
| --- | --- |
| University of Alabama at Birmingham | “Birmingham” |
| University of Arizona (Surgical Site Only) | “Tucson” |
| University of California, San Francisco | “San Francisco” |
| CenExel Rocky Mountain Clinical Research | “Englewood” |
| Rush University Medical Center | “Chicago” |
| Johns Hopkins University | “Baltimore” |
| University of Michigan Department of Neurology | “Ann Arbor” |
| Ohio State University | “Columbus” |
| Vanderbilt University Medical Center | “Nashville” |
| The University of Texas | “Houston” |
| Virginia Commonwealth University VCU School of Medicine, Department of Neurology | “Richmond” |
| University of Washington Medical Center | “Seattle” |

Source: [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493)

<a id="topic-3.1.2.2-2"></a>

#### Study dates in the registry record

| Date | Registry value |
| --- | --- |
| Study start (actual) | “2019-09-06” |
| Primary completion (estimated) | “2029-06” |
| Study completion (estimated) | “2029-12” |
| Last update posted | “2025-10-21” |

Source: [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493)

<a id="topic-3.1.2.2-3"></a>

#### First participants treated in the United States, June 2020

> “today announced that the first two patients in the Phase I/II clinical trial of AMT-130 for the treatment of Huntington’s disease have been treated.”
> “The Phase I/II study is a double-blind, randomized clinical trial being conducted in the United States, with now one patient treated with AMT-130, and one patient who received the imitation surgery.”

Source: [uniQure press release, first patients treated (2020)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-first-two-patients-treated-phase-iii-clinical)

<a id="topic-3.1.2.2-4"></a>

#### Study dates in the original registry record, October 2019, superseded

| Field | Registry value |
| --- | --- |
| Version | “Viewing V1 (2019-10-07)” |
| Study start | “2019-10 [Estimated]” |
| Primary completion | “2022-12 [Estimated]” |
| Study completion | “2026-05 [Estimated]” |

Source: [ClinicalTrials.gov NCT04120493 version 1](https://clinicaltrials.gov/study/NCT04120493?tab=history&a=1)

<a id="heading-3.1.2.3"></a>

### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

#### Design in the current registry record

> “A Phase 1/2, Randomized, Double-Blind, Sham Control and Open-Label Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Doses of Striatally-Administered rAAV5-miHTT Total Huntingtin Gene (HTT) Lowering Therapy (AMT-130) in Early Manifest Huntington's Disease”
> “CT-AMT-130-01 is a Phase 1/2, multicenter, first-in-human (FIH) study.”
> “The first three cohorts of the study have completed enrollment, including the randomized, double-blind, sham-controlled cohorts.”
> “Cohort 4 is open-label.”

Source: [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493)

<a id="topic-3.1.2.3-2"></a>

#### Design fields in the current registry record

| Field | Registry value |
| --- | --- |
| Allocation | “Non-Randomized” |
| Intervention model | “Sequential” |
| Masking | “None (Open Label)” |

Source: [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493)

<a id="topic-3.1.2.3-3"></a>

#### Follow-up duration by cohort

> “Cohorts 1 and 2 participants continue follow-up visits through 6 years after receipt of AMT-130. Cohorts 3 and 4 participants continue follow-up visits through 5 years after receipt of AMT-130.”

Source: [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493)

<a id="topic-3.1.2.3-4"></a>

#### Randomized, quadruple-masked parallel design with an 18-month core period: registry version 1, October 2019, superseded

| Field | Registry value |
| --- | --- |
| Official title | “A Phase I/II, Randomized, Double-blind, Sham Control Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Ascending Doses of Striatally-Administered rAAV5-miHTT Total Huntingtin Gene (HTT) Lowering Therapy (AMT-130) in Early Manifest Huntington Disease” |
| Interventional study model | “Parallel Assignment” |
| Masking | “Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)” |
| Allocation | “Randomized” |
| Enrollment | “26 [Estimated]” |

Source: [ClinicalTrials.gov NCT04120493 version 1](https://clinicaltrials.gov/study/NCT04120493?tab=history&a=1)

> “CT-AMT-130-01 is a Phase I/II, randomized, multicenter, dose escalation, double-blind, imitation surgery, first-in-human (FIH) study.”
> “This 5-year trial consists of a blinded 18-month Core Study Period to evaluate the safety and potential impact of AMT-130 on disease progression and an unblinded 3.5-year Long-Term Period with annual follow-up visits to evaluate the safety of AMT-130 and disease progression.”

Source: [ClinicalTrials.gov NCT04120493 version 1](https://clinicaltrials.gov/study/NCT04120493?tab=history&a=1)

<a id="topic-3.1.2.3-5"></a>

#### Randomized, triple-masked sequential design with crossover: registry version 33, October 2024, superseded

| Field | Registry value |
| --- | --- |
| Version | “Viewing V33 (2024-10-22)” |
| Interventional study model | “Sequential Assignment” |
| Masking | “Triple (Participant, Investigator, Outcomes Assessor)” |
| Allocation | “Randomized” |
| Enrollment | “37 [Estimated]” |

Source: [ClinicalTrials.gov NCT04120493 version 33](https://clinicaltrials.gov/study/NCT04120493?tab=history&a=33)

> “Cohort 1 & 2 consists of a blinded 12-month Core Study Period to evaluate the safety and potential impact of AMT-130 on disease progression and an unblinded 4-year Long-Term Period with periodic follow-up visits to evaluate the safety of AMT-130 and disease progression in treated individuals.”
> “Cohort 2 Sham participants who do not cross over to receive AMT-130 treatment will have the opportunity to participate in the Optional Extended Follow-Up Period and will be followed for an additional 2 years.”
> “Following completion of the 12-month blinded post treatment follow-up period (Cohorts 1 & 2 only), once the crossover has been activated after review of data by the DSMB, subjects randomized to the imitation (sham) procedure who continue to meet inclusion/exclusion criteria will be allowed to crossover to receive AMT-130 treatment.”
> “Cohort 3 participants will receive either high or low dose AMT-130. Following completion of the Month 36 visit, they will be unblinded to their treatment arm.”

Source: [ClinicalTrials.gov NCT04120493 version 33](https://clinicaltrials.gov/study/NCT04120493?tab=history&a=33)

<a id="topic-3.1.2.3-6"></a>

#### Blinded core period of 18 months at first dosing, June 2020, superseded

> “The five-year, multi-center trial consists of a blinded 18-month core study period followed by unblinded long-term follow-up.”

Source: [uniQure press release, first patients treated (2020)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-first-two-patients-treated-phase-iii-clinical)

<a id="topic-3.1.2.3-7"></a>

#### Blinded 12-month core period followed by five years of follow-up, March 2022

> “The Phase I/II clinical trial consists of a blinded 12-month period followed by unblinded long-term follow-up for five years.”

Source: [uniQure press release, enrollment of first two cohorts (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-completion-patient-enrollment-first-two)

<a id="topic-3.1.2.3-8"></a>

#### Cohort 3 as first planned: alternative stereotactic navigation, December 2021, superseded in June 2023

> “uniQure also plans to initiate a third cohort in the ongoing U.S. Phase I/II clinical trial in the second half of 2022 that will explore the use of alternative stereotactic navigation systems to simplify placement of catheters for infusions of AMT-130.”
> “This will be explored in two steps and include up to 18 additional randomized patients who will receive the higher dose of 6x1013 vg.”

Source: [uniQure press release, clinical update on first patients (2021)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-clinical-update-first-patients-phase-iii)

<a id="topic-3.1.2.3-9"></a>

#### Cohort 3 redesigned to study perioperative immunosuppression, June 2023

> “In the second half of 2023, uniQure expects to initiate a third cohort in the ongoing U.S. clinical trial to further investigate both doses in combination with perioperative immunosuppression with a focus on evaluating near-term safety.”

Source: [uniQure press release, U.S. interim data (2023)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-us-phase-iii-clinical-trial-amt-130)

<a id="topic-3.1.2.3-10"></a>

#### Cohort 3: blinded randomization to high or low dose

> “Patients were blinded and randomized to receive either the high (n=6) or low dose (n=6) of AMT-130 in conjunction with an immunosuppression regimen.”

Source: [uniQure press release, first quarter 2025 results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-first-quarter-2025-financial-results-and)

<a id="topic-3.1.2.3-11"></a>

#### Cohort 4: high dose in participants with lower striatal volumes

> “Q3 2025: Initiate a fourth cohort evaluating high-dose AMT-130 in six patients with lower striatal volumes compared to those of patients enrolled in previous cohorts.”

Source: [uniQure press release, second quarter 2025 results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-second-quarter-2025-financial-results-and)

<a id="heading-3.1.2.4"></a>

### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

#### Inclusion criteria in the current registry record

> “Participants 25 to 65 years of age of both sexes”
> “Early manifest HD as defined by a UHDRS total functional capacity (TFC) score of 9 to 13 and EITHER a diagnostic confidence level (DCL) of 4 OR a DCL of 3 if the subject either meets the definition of multidimensional manifest HD (UHDRS question 80) or has cognitive symptoms”
> “Cohort 3: Early manifest HD as defined by a UHDRS TFC score of ≥ 11”
> “HTT gene expansion testing with the presence of ≥40 CAG repeats”

Source: [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493)

<a id="topic-3.1.2.4-2"></a>

#### Striatal volume criteria: minimum volumes in Cohorts 1 to 3 and lower volumes in Cohort 4

> “Cohorts 1, 2, & 3: Putamen ≥2.5 cm^3 (per side); Caudate ≥2.0 cm^3 (per side)”
> “Cohort 4: Putamen <2.5 cm^3 (on either side); Caudate <2.0 cm^3 (on either side)”
> “Cohort 4 ONLY: Inability to establish a safe trajectory to administer AMT-130 to the target structures, as assessed by neuroimaging.”

Source: [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493)

<a id="topic-3.1.2.4-3"></a>

#### Selected exclusion criteria in the current registry record

> “Evidence of suicide risk”
> “Presence of an implanted deep brain stimulation device, ventriculoperitoneal or other CSF shunt, or other implanted catheter”
> “Brain and spinal pathology that may interfere with the surgical delivery of AMT-130 or represents a significant neurologic comorbid disorder”

Source: [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493)

<a id="topic-3.1.2.4-4"></a>

#### Eligibility in the original registry record, October 2019, superseded

> “First 4 subjects in Cohort 1: early manifest HD (Stage 2). All remaining subjects in Cohort 1 and all subjects in Cohort 2: early manifest HD (Stages 1 and 2).”
> “HTT gene expansion testing with the presence of ≥44 CAG repeats.”
> “Striatal MRI volume requirements per hemisphere: Putamen ≥2.5 cm3 (per side); Caudate ≥2.0 cm3 (per side)”

Source: [ClinicalTrials.gov NCT04120493 version 1](https://clinicaltrials.gov/study/NCT04120493?tab=history&a=1)

<a id="heading-3.1.2.5"></a>

### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

#### Doses and route in the current registry record

> “Low dose rAAV5-miHTT (6x10^12 gc/subject).”
> “High dose rAAV5-miHTT (6x10^13 gc/subject).”

Source: [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493)

<a id="topic-3.1.2.5-2"></a>

#### Imitation (sham) surgery in Cohorts 1 and 2

> “Simulated surgical procedure with skin incisions only; no intrastriatal injections and no burr holes through the skull”

Source: [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493)

<a id="topic-3.1.2.5-3"></a>

#### Imitation surgery with partial-thickness burr holes: registry version 1, October 2019, superseded

> “Imitation surgery patients randomized across both Cohort 1 and 2”
> “Bilateral partial thickness burr holes placed, no intrastriatal injections”
> “Intrastriatal administration of low dose rAAV5-miHTT (6E12 gc/subject). Single dose administration.”

Source: [ClinicalTrials.gov NCT04120493 version 1](https://clinicaltrials.gov/study/NCT04120493?tab=history&a=1)

<a id="topic-3.1.2.5-4"></a>

#### Treatment allocation in Cohorts 1 and 2

> “In the U.S. study, 26 patients with early manifest Huntington’s disease were randomized to treatment (six low-dose patients, 10 high-dose patients) or an imitation (sham) surgical procedure (10 patients).”

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

<a id="topic-3.1.2.5-5"></a>

#### Administration procedure in Cohorts 1 and 2

> “The treated patients have received a single administration of AMT-130 using MRI-guided, convection-enhanced stereotactic neurosurgical delivery directly into the striatum (caudate and putamen).”

Source: [uniQure press release, enrollment of first two cohorts (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-completion-patient-enrollment-first-two)

<a id="topic-3.1.2.5-6"></a>

#### Cohort 3: established administration procedure

> “The third cohort will enroll up to 10 patients, all of whom will receive AMT-130 using the current, established stereotactic neurosurgical delivery procedure.”

Source: [uniQure press release, U.S. interim data (2023)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-us-phase-iii-clinical-trial-amt-130)

<a id="topic-3.1.2.5-7"></a>

#### Cohort 4: high dose with perioperative dexamethasone

> “All participants in Cohort 4 will receive high dose AMT-130 and will receive pre- and post-operative dexamethasone.”

Source: [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493)

<a id="heading-3.1.2.6"></a>

### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

#### 3.1.2.6.1 Rationale for Using Adverse Events as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

##### Primary outcome: number and type of adverse events at 12 months

> “Safety will be assessed by adverse events (AEs) related to clinical safety laboratory tests, vital signs, electrocardiograms (ECGs), neurological and physical examinations, rAAV5 vector shedding, immunogenicity response”
> “12 months (Cohorts 1 & 2) and 12 months (Cohort 3)”

Source: [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493)

<a id="topic-3.1.2.6.1-2"></a>

##### First-in-human trial with staged dosing reviewed by the Data Safety Monitoring Board

> “Milestone Marks the First-in-Human AAV Gene Therapy Trial for Huntington’s Disease”
> “The first two patients will be observed for an initial period of 90 days, followed by a meeting of the Data Safety Monitoring Board (DSMB).”
> “The DSMB will review the data on the first two patients and make a determination about continued dosing of the next patients.”

Source: [uniQure press release, first patients treated (2020)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-first-two-patients-treated-phase-iii-clinical)

<a id="topic-3.1.2.6.1-3"></a>

##### Secondary outcome: persistence of AMT-130 in the brain

> “Duration of persistence of AMT-130 in the brain”
> “Change over time in levels of AMT-130-derived Vector DNA Expression in the Cerebrospinal Fluid (CSF)”
> “Collected for duration of study through month 72 (Cohorts 1 & 2) and through month 16 (Cohorts 3 & 4)”

Source: [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493)

<a id="topic-3.1.2.6.1-4"></a>

##### Exploratory outcomes in the current registry record

| Exploratory outcome | Registry entry |
| --- | --- |
| Cerebrospinal fluid mutant huntingtin | “CSF Mutant Protein (fM)” |
| Neurofilament light chain | “CSF/Serum Neurofilament Light Chain (pg/mL)” |
| Rating scale | “Unified Huntington Disease Rating Scale (UHDRS)” |
| Quantitative motor testing | “Quantitative Motor (Q-Motor) Testing” |
| Imaging | “Magnetic Resonance Imaging (MRI)” |
| Health-related quality of life | “Neuro-QoL Measures” |

Source: [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493)

> “Will be used as an exploratory biomarker to measure disease progression and responsiveness to AMT-130 treatment.”
> “The UHDRS will assess changes from baseline in summary scores of domains of motor function, cognitive function, behavioral function, and functional abilities.”
> “MRI assessments will include whole brain volume, striatal region volumes, white matter volume, gray matter volume, ventricular volume, cortical thickness, and diffusion MRI measures.”
> “The Neuro-QoL is a brief, reliable, valid, standardized set of patient reported, Health Related Quality of Life (HRQoL) measures for people living with neurological conditions.”

Source: [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493)

<a id="topic-3.1.2.6.1-5"></a>

##### Additional exploratory outcomes in registry version 1, October 2019

> “The HD-CAB measures cognitive dysfunction in late premanifest and early manifest HD patients.”
> “MRS will be collected using single-voxel point resolved spectroscopy of the left putamen and white matter region immediately adjacent to the left putamen.”
> “The HDQLIFE is a measurement system that was designed to provide a brief, reliable and valid assessment of HRQoL in HD and consists of NeuroQoL measures that have been validated in the HD population and several new HD specific measures.”
> “The HADS is a 14-item, self-report measure that has been shown to be reliable and valid for identifying depression and anxiety in adults who are physically ill.”

Source: [ClinicalTrials.gov NCT04120493 version 1](https://clinicaltrials.gov/study/NCT04120493?tab=history&a=1)

<a id="topic-3.1.2.6.1-6"></a>

##### Limitation of cerebrospinal fluid mutant huntingtin as a measure of brain levels

> “Given AMT-130 is directly administered deep within the brain, the pharmacodynamics of mHTT in the CSF are not believed to be materially representative of mHTT in the targeted brain regions.”

Source: [uniQure press release, interim data update (2023)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-phase-iii-clinical-trials-amt-130-gene)

<a id="heading-3.1.2.7"></a>

### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

#### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

##### Planned enrollment at first dosing, June 2020, superseded

> “The Phase I/II clinical trial of AMT-130 for the treatment of Huntington’s disease will explore the safety, tolerability, and efficacy signals in 26 patients with early manifest Huntington’s disease randomized to treatment with AMT-130 or an imitation (sham) surgery.”

Source: [uniQure press release, first patients treated (2020)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-first-two-patients-treated-phase-iii-clinical)

<a id="topic-3.1.2.7.1-2"></a>

##### Participants in Cohorts 1 and 2 by arm

> “The first dose cohort includes 10 patients, of which six patients received treatment with AMT-130 and four patients received imitation surgery.”
> “The second dose cohort includes 16 patients, of which ten patients received treatment with AMT-130 and six patients received imitation surgery.”

Source: [uniQure press release, enrollment of first two cohorts (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-completion-patient-enrollment-first-two)

<a id="topic-3.1.2.7.1-3"></a>

##### Planned size of Cohort 3, December 2023

> “In the fourth quarter of 2023, the Company initiated patient dosing in a third cohort of up to 12 patients to further investigate both doses of AMT-130 in combination with perioperative immunosuppression, with a focus on evaluating near-term safety and tolerability.”

Source: [uniQure press release, full year 2023 results (2024)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-2023-financial-results-and-highlights-recent)

<a id="topic-3.1.2.7.1-4"></a>

##### Estimated total enrollment in the current registry record

| Field | Registry value |
| --- | --- |
| Enrollment (estimated) | “43” |

Source: [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493)

<a id="heading-3.1.2.7.2"></a>

#### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

##### Participants evaluable for biomarkers in the low-dose cohort, June 2022

> “Ten patients were evaluable for NfL measurements. Four treated and three control patients were evaluable for mHTT protein in the CSF measurements. The remaining two treated patients and one control patient did not have a measurable baseline CSF mHTT value.”

Source: [uniQure press release, low-dose cohort update (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-low-dose-cohort-phase-iii-clinical)

<a id="topic-3.1.2.7.2-2"></a>

##### Comparators and exclusion of crossover participants in the June 2023 interim analysis

> “Efficacy and biomarker data from the crossover patients are not included in the summary below.”
> “Clinical and functional measurements for treated patients in each dose cohort were compared to baseline measurements, control patients (up to 12 months) and a natural history cohort.”
> “The cohort includes 31 patients that met the uniQure clinical trial inclusion-criteria of CAG length, age, Total Functional Capacity, Diagnostic Classification Level and minimum striatal volumes.”

Source: [uniQure press release, U.S. interim data (2023)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-us-phase-iii-clinical-trial-amt-130)

<a id="heading-3.1.2.8"></a>

### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

#### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

##### Enrollment progress, December 2021

> “Nineteen patients have been enrolled in the clinical trial to date, including 9 of 16 in the higher-dose cohort.”

Source: [uniQure press release, clinical update on first patients (2021)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-clinical-update-first-patients-phase-iii)

<a id="topic-3.1.2.8.1-2"></a>

##### Enrollment of Cohorts 1 and 2 completed, March 2022

> “today announced the completion of patient enrollment in the first two cohorts of its randomized, double-blinded, Phase I/II clinical trial of AMT-130 for the treatment of early stage Huntington’s disease.”

Source: [uniQure press release, enrollment of first two cohorts (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-completion-patient-enrollment-first-two)

<a id="topic-3.1.2.8.1-3"></a>

##### Crossover of control participants, 2022 to 2023

> “One control patient from the higher-dose cohort was successfully crossed over to treatment in the third quarter of 2022 and received the lower dose of AMT-130.”

Source: [uniQure press release, third quarter 2022 results (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-third-quarter-2022-financial-results-and)

> “In the first quarter of 2023, a second control patient was crossed over to treatment and received the higher dose of AMT-130.”

Source: [uniQure press release, full year 2022 results (2023)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-2022-financial-results-and-highlights-recent)

> “Four of the six control patients in the high-dose cohort were crossed over to treatment and the remaining two patients failed to meet the study’s inclusion criteria.”

Source: [uniQure press release, interim data update (2023)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-phase-iii-clinical-trials-amt-130-gene)

<a id="topic-3.1.2.8.1-4"></a>

##### Cohort 3 enrollment completed, February 2025

> “In February 2025, the Company completed enrollment of all 12 patients in the third cohort of the Phase I/II study.”

Source: [uniQure press release, first quarter 2025 results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-first-quarter-2025-financial-results-and)

<a id="topic-3.1.2.8.1-5"></a>

##### Cohort 4 recruited in October 2025 and dosed in the fourth quarter of 2025

> “In October 2025, the Company initiated and fully recruited a fourth cohort evaluating high-dose AMT-130 in six patients with lower striatal volumes compared to patients in previous cohorts.”

Source: [uniQure press release, third quarter 2025 results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-third-quarter-2025-financial-results-and)

> “In the fourth quarter of 2025, dosing was completed in a fourth cohort of six patients receiving high-dose AMT-130 to evaluate safety and efficacy in patients with lower baseline striatal volumes compared to previous cohorts in the U.S. Phase I/II study.”

Source: [uniQure press release, full year 2025 results (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-2025-financial-results-and-provides-recent)

<a id="heading-3.1.2.8.2"></a>

#### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

##### First four participants in the low-dose cohort, December 2021

> “The first four patients were a heterogeneous group representing a spectrum of Stage I-II early manifest disease with 41-44 CAG repeats, baseline Total Functional Capacity scores of 10-13 and Total Motor Scores of 7-23.”

Source: [uniQure press release, clinical update on first patients (2021)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-clinical-update-first-patients-phase-iii)

<a id="topic-3.1.2.8.2-2"></a>

##### Low-dose cohort of 10 participants, June 2022

> “The 10 patients enrolled in the low-dose cohort were all clinically diagnosed with early-stage Huntington’s disease with CAG repeats between 40-44, baseline Total Functional Capacity scores of 10-13, and Total Motor Scores of 7-23.”
> “Four patients were male and six were female with ages ranging from 34-58 years old. Demographics of the six treated patients were generally consistent with the four control patients.”

Source: [uniQure press release, low-dose cohort update (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-low-dose-cohort-phase-iii-clinical)

<a id="topic-3.1.2.8.2-3"></a>

##### Cohort 4 baseline characteristics

| Characteristic (mean or %) | AMT-130 high-dose Cohort 4 (n=6) |
| --- | --- |
| Sex, males (%) | “16.7” |
| Age | “43.7” |
| CAG repeats | “44.5” |
| DCL = 3, 4 (%) | “16.7, 83.3” |
| TFC | “12.0” |

Source: [Margolin et al. (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/CHDI-2026Feb-AMT-130-striatal-volumes-FINAL-PDF.pdf)

<a id="heading-3.1.2.8.3"></a>

#### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

##### First four participants at one year, December 2021

> “NfL increased as expected immediately following the AMT-130 surgical procedure and returned to baseline in the two treated patients. NfL remained relatively constant in the two untreated control patients.”
> “Measurements of total and mutant HTT protein in the cerebral spinal fluid of the four patients were highly variable and inconclusive.”

Source: [uniQure press release, clinical update on first patients (2021)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-clinical-update-first-patients-phase-iii)

<a id="topic-3.1.2.8.3-2"></a>

##### Low-dose cohort at 12 months: cerebrospinal fluid mutant huntingtin, June 2022

> “In the four treated patients with evaluable data, mean levels of CSF mHTT declined compared to baseline at all available timepoints. At 12 months after treatment, mean CSF mHTT decreased 53.8% compared to baseline (range 44% decrease to 71% decrease).”
> “In the three control patients with evaluable data, mean CSF mHTT showed an increase compared to baseline at one, three, six and nine months, and decreased by 16.8% compared to baseline at 12 months (range 35% increase to 47% decrease).”

Source: [uniQure press release, low-dose cohort update (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-low-dose-cohort-phase-iii-clinical)

<a id="topic-3.1.2.8.3-3"></a>

##### Low-dose cohort at 12 months: cerebrospinal fluid neurofilament light chain, June 2022

> “In the six treated patients, the increase in mean CSF NfL peaked one month after the surgical procedure. Thereafter, mean CSF NfL declined and at 12 months showed an 8% increase compared to baseline (range 46% increase to 14% decrease).”
> “In the four control patients, mean CSF NfL remained stable or slightly declined over 12 months (range 1% increase to 35% decrease).”

Source: [uniQure press release, low-dose cohort update (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-low-dose-cohort-phase-iii-clinical)

<a id="topic-3.1.2.8.3-4"></a>

##### U.S. interim analysis: clinical measures against baseline, controls, and a TRACK-HD natural history cohort, June 2023

> “Compared to baseline measurements, clinical function was generally preserved at 24 months for patients in the low-dose cohort and at 12 months for patients in the high-dose cohort.”
> “Total Motor Score (TMS): Low-dose patients demonstrated a mean improvement in TMS of 1.8 points at 24 months compared to natural history and high-dose patients demonstrated a mean improvement of 2.7 points at 12 months.”
> “Total Functional Capacity (TFC): Low-dose patients demonstrated a mean 0.8 point improvement in TFC at 24 months compared to natural history and high-dose patients demonstrated a mean 0.5 point improvement at 12 months.”
> “Composite Unified Huntington’s Disease Rating Scale (cUHDRS): Low-dose patients demonstrated a mean 0.9 point improvement in cUHDRS at 24 months compared to natural history and high-dose patients demonstrated a mean 1.0 point improvement at 12 months.”
> “Patients in the control group experienced a worsening of Total Motor Score at 12 months compared to baseline and natural history. TFC and cUHDRS was preserved in control patients at 12 months.”

Source: [uniQure press release, U.S. interim data (2023)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-us-phase-iii-clinical-trial-amt-130)

<a id="topic-3.1.2.8.3-5"></a>

##### U.S. interim analysis: biomarkers and brain volume, June 2023

> “Mean CSF NfL for the low-dose cohort was 12.9% below baseline compared to a predicted 22.9% increase in the natural history, with four of the five low-dose patients having CSF NfL levels below baseline.”
> “CSF NfL levels in the high-dose cohort were more variable through 12 months, with a mean increase of 51.5% compared to baseline. Four of the eight high-dose patients with at least 12 months of follow-up had NfL levels below baseline.”
> “In the control group, mean CSF NfL was relatively stable and was 6.83% below baseline at 12 months.”
> “CSF mHTT for the low-dose cohort remained below baseline with a mean reduction of 8.1% at 24 months. CSF mHTT for the high-dose cohort was significantly more variable with a mean increase of 39.7% above baseline at 12 months compared to a 4.7% increase in the control group.”
> “The mean total brain volume for the control, low-dose and high-dose cohorts declined 0.74%, 1.02% and 1.23%, respectively at 12 months and were not significantly different from each other or from the natural history.”

Source: [uniQure press release, U.S. interim data (2023)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-us-phase-iii-clinical-trial-amt-130)

<a id="topic-3.1.2.8.3-6"></a>

##### Cohort 3: perioperative neurofilament light chain

> “Perioperative changes in CSF NfL were consistent with previously reported observations, reinforcing their association with the surgical administration.”

Source: [uniQure press release, first quarter 2025 results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-first-quarter-2025-financial-results-and)

<a id="heading-3.1.2.8.4"></a>

#### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.2.8.5"></a>

#### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

##### First four participants at one year, December 2021

> “There have been no serious adverse events (SAEs) to date related to AMT-130 in these patients.”
> “Structural magnetic resonance imaging did not reveal any clinically meaningful safety findings in either treated or control patients at one year of follow-up.”

Source: [uniQure press release, clinical update on first patients (2021)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-clinical-update-first-patients-phase-iii)

<a id="topic-3.1.2.8.5-2"></a>

##### Low-dose cohort at 12 months: deep vein thrombosis and postoperative delirium, June 2022

> “No serious adverse events related to AMT-130 were reported in these patients. Two serious adverse events unrelated to AMT-130 occurred: a deep-vein thrombosis in the elbow in one patient that resolved with anticoagulants and transient post-operative delirium in a second patient that was resolved through supportive care.”
> “No adverse drug reactions or serious unexpected adverse reactions were reported.”

Source: [uniQure press release, low-dose cohort update (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-low-dose-cohort-phase-iii-clinical)

<a id="topic-3.1.2.8.5-3"></a>

##### High-dose procedures paused after suspected unexpected serious adverse reactions, August 2022

> “In July, we reported to the health authorities suspected unexpected severe adverse reactions in three of the 14 patients treated with the higher dose of AMT-130”
> “A third patient, who had previously been treated with the higher-dose of AMT-130 in the U.S. during March 2022, experienced severe headache and other related symptoms soon after AMT-130 administration that was initially deemed by the investigator as not related to AMT-130 but related to the procedure.”
> “Upon further review and discussion with the clinical trial’s independent Data Safety Monitoring Board (DSMB) following the events observed in the European study, the Company has reclassified and reported the patient reaction in the U.S. trial as a SUSAR.”

Source: [uniQure press release, second quarter 2022 results (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-second-quarter-2022-financial-results-and)

<a id="topic-3.1.2.8.5-4"></a>

##### High-dose treatment resumed with additional monitoring, October 2022

> “In October 2022, the DSMB reviewed all available safety, biomarker and imaging data from the ongoing Phase I/II clinical trials of AMT-130 and recommended resuming treatment at the higher dose.”
> “The DSMB recommended implementing additional risk mitigation procedures during the first two weeks after the surgical administration of AMT-130, including a seven-day, in-person post-surgical visit.”

Source: [uniQure press release, third quarter 2022 results (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-third-quarter-2022-financial-results-and)

<a id="topic-3.1.2.8.5-5"></a>

##### U.S. interim analysis: serious adverse events and suspected unexpected serious adverse reactions, June 2023

> “The most common adverse events in the treatment groups were related to the surgical procedure. No treatment emergent adverse events (TEAEs) led to discontinuation of patient follow-up.”
> “As previously reported, there were two serious adverse events (SAE) unrelated to AMT-130 (post-operative delirium and major depression) in the low-dose cohort, one SAE in the high-dose cohort (back pain), and one SAE (deep vein thrombosis) in the control group. In addition there were two suspected unexpected serious adverse events (severe headache, central nervous system inflammation) in the high-dose cohort. All the events have resolved.”
> “Following a review of the interim data analysis, the Data Safety Monitoring Board (DSMB) for the U.S. Phase I/II clinical trial concluded there are no safety concerns with either dose and recommended continuing clinical development of AMT-130.”

Source: [uniQure press release, U.S. interim data (2023)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-us-phase-iii-clinical-trial-amt-130)

<a id="topic-3.1.2.8.5-6"></a>

##### Cohort 3: serious adverse events related to immunosuppression

> “AMT-130 was generally well-tolerated at both dose levels;”
> “No treatment-related serious adverse events were reported;”
> “Three serious adverse events related to immunosuppression (mania, infection, and fever) were observed; all resolved fully with supportive care and;”

Source: [uniQure press release, first quarter 2025 results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-first-quarter-2025-financial-results-and)

<a id="topic-3.1.2.8.5-7"></a>

##### Cohort 4: treatment-related central nervous system inflammation

> “One treatment-related SAE of CNS inflammation in a Cohort 4 patient, fully resolved following a short course of corticosteroids”

Source: [uniQure presentation, four-year data (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Sept-2026-Data-Update_Final.pdf)

<a id="heading-3.1.2.9"></a>

### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

#### Summary

- Changed blinding and registry inconsistencies: the current ClinicalTrials.gov record lists allocation as non-randomized and masking as none (open label), while its official title describes a randomized, double-blind, sham control and open-label study. Version 1 (2019) listed a randomized, quadruple-masked design with an estimated enrollment of 26 and a blinded 18-month core period; version 33 (2024) listed a randomized, triple-masked design with an estimated enrollment of 37 and a blinded 12-month core period; the current record lists an estimated enrollment of 43. Cohort 4 is open-label.
- Short randomized comparison: the sham comparison in Cohorts 1 and 2 covered the blinded 12-month period, after which sham participants could cross over. Four of the six control participants in the high-dose cohort crossed over and the other two did not meet the inclusion criteria, and interim analyses compared treated participants with control participants only up to 12 months and excluded efficacy data from crossover participants.
- Small numbers: Cohorts 1 and 2 randomized 26 participants (six low dose, 10 high dose, 10 sham); Cohort 3 enrolled 12 and Cohort 4 six.
- Safety as the primary outcome: the study is designed to establish safety and proof-of-concept, and the registered primary outcome is adverse events at 12 months.
- Target engagement: the company states that CSF mutant huntingtin is not believed to be materially representative of mutant huntingtin in the targeted brain regions, and one commentary noted that there are no data on mutant HTT lowering.
- Protocol changes: version 1 required ≥44 CAG repeats and an imitation surgery with bilateral partial thickness burr holes; the current record requires ≥40 CAG repeats and a simulated procedure with skin incisions only and no burr holes. Cohort 3 was first planned to study alternative stereotactic navigation systems and was redesigned to study perioperative immunosuppression.

Source: [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493); [ClinicalTrials.gov NCT04120493 version 1](https://clinicaltrials.gov/study/NCT04120493?tab=history&a=1); [ClinicalTrials.gov NCT04120493 version 33](https://clinicaltrials.gov/study/NCT04120493?tab=history&a=33); [uniQure press release, interim data update (2023)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-phase-iii-clinical-trials-amt-130-gene); [uniQure press release, U.S. interim data (2023)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-us-phase-iii-clinical-trial-amt-130); [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm); [uniQure press release, first quarter 2025 results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-first-quarter-2025-financial-results-and); [uniQure press release, full year 2025 results (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-2025-financial-results-and-provides-recent); [Minikel (2025)](https://www.cureffi.org/2025/10/08/amt-130/); [uniQure press release, clinical update on first patients (2021)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-clinical-update-first-patients-phase-iii)

## Related pages
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Terms and abbreviations](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations.md)
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Product information and disease description](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Clinical evidence](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic information and modeling report](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: References](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references.md)
